Post-effective amendment to a registration statement that is not immediately effective upon filing

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.22.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Series C Preferred Stock
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Common Stock
Common Stock
Series A Preferred Stock
Common Stock
Series B Preferred Stock
Common Stock
Series C Preferred Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A Preferred Stock
Additional Paid-in Capital
Series B Preferred Stock
Additional Paid-in Capital
Series C Preferred Stock
AOCI Attributable to Parent
Accumulated Deficit
Beginning balance at Dec. 31, 2019 $ (18,655)   $ 52,809 $ 35,228 $ 65,222 $ 2       $ 7,354       $ (628) $ (178,642)
Beginning balance, shares at Dec. 31, 2019 [1]     21,615,723 8,306,818 12,804,176 17,602,594                  
Exercise of stock options 75                 75          
Number of Stock Options Exercised [1]           61,421                  
Stock compensation expense 2,160                 2,160          
Issuance of stock warrants 542                 542          
Net loss (32,504)                           (32,504)
Foreign currency translation adjustments (354)                         (354)  
Ending balance at Dec. 31, 2020 (48,736)   $ 52,809 $ 35,228 $ 65,222 $ 2       10,131       (982) (211,146)
Ending balance, shares at Dec. 31, 2020 [1]     21,615,723 8,306,818 12,804,176 17,664,015                  
Exercise of stock options $ 1,289                 1,289          
Number of Stock Options Exercised 923,200 [2]         923,200 [1]                  
Stock compensation expense $ 11,634                 11,634          
Issuance of common stock relating to the acquisition 19,362         $ 1       19,361          
Issuance of common stock relating to the acquisition [1]           5,230,167                  
Issuance of shares to FP Lenders (Note 8) 22,868                 22,868          
Issuance of shares to FP Lenders (Note 8) [1]           2,468,492                  
Exercise of Series C preferred warrants 891       $ 891                    
Exercise of Series C preferred warrants, Shares   146,919     146,919 [1]                    
Conversion of warrants to common stock 308                 308          
Conversion of warrants to common stock, Share [1]           672,355                  
Conversion of convertible notes to common stock 70,933   $ (52,809) $ (35,228) $ (66,113) $ 4 $ 2 $ 1 $ 1 70,929 $ 52,807 $ 35,227 $ 66,112    
Conversion of convertible notes to common stock, shares [1]     (21,615,723) (8,306,818) (12,951,095) 37,034,620 21,615,723 8,306,818 12,951,095            
Issuance of common stock upon the reverse recapitalization and PIPE financing, net of merger costs [1],[3] 206,308         $ 4       206,304          
Issuance of common stock upon the reverse recapitalization and PIPE financing, net of merger costs [1],[3]           44,288,129                  
Contingent earnout liability upon closing of the merger (78,395)                 (78,395)          
Net loss (19,312)                           (19,312)
Foreign currency translation adjustments 1,714                         1,714  
Ending balance at Dec. 31, 2021 $ 188,864         $ 15       $ 418,575       $ 732 $ (230,458)
Ending balance, shares at Dec. 31, 2021 [1]           151,154,614                  
[1] The shares of the Company’s common and convertible preferred stock, prior to the Merger (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 1.7058 established in the Merger as described in Note 3.
[2] These amounts have been adjusted to correctly present the prior period activity and options outstanding at December 31, 2020.
[3] Included in the share number is 12,058,614 shares of Class B common stock.